contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


dicot-pharma-ab-dicot-pharma-invites-to-a-qanda-session-on-to-6

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Dicot Pharma utvecklar läkemedelskandidaten LIB-01 vilket förväntas bli ett potensläkemedel för att behandla erektionssvikt och tidig utlösning. Verkningstid och färre biverkningar är huvudsakliga önskade egenskaper. Dicots huvudstrategi är att under utvecklingen av LIB-01 löpande utvärdera industriella partnerskap för att ta läkemedelskandidaten fram till kommersialisering.

Dicot Pharma

Uppsala, March 17, 2025. Dicot Pharma invites to a Q&A session regarding the ongoing exercise of warrants in TO 6. The Q&A session will take place via Zoom on March 20 at 12.30. The session ...

<div class="abstract">Uppsala, March 17, 2025. Dicot Pharma invites to a Q&amp;A session regarding the ongoing exercise of warrants in TO 6. The Q&amp;A session will take place via Zoom on March 20 at 12.30. The session will be held in Swedish.</div>Dicot Pharma's warrants of series TO 6 have a redemption period and can be exercised March 17-31. To answer any questions, a Q&amp;A session in Swedish will take place via Zoom on Thursday, March 20 at 12.30 and will also be available for viewing afterwards.&nbsp;Questions can be asked online at the session or before via <a style="text-decoration:none" href="mailto:info@dicotpharma.com">info@dicotpharma.com</a>.&nbsp;CEO Elin Trampe comments: "We want to enable our existing but also potential new warrant holders to ask questions live directly to the company. We will start with a short status update and then open up for questions."&nbsp;To register to attend the live Q&amp;A session, please go to<a style="text-decoration:none" href="https://us02web.zoom.us/webinar/register/WN_kZrwRSWgT5eQur7vueiMIQ">https://us02web.zoom.us/webinar/register/WN_kZrwRSWgT5eQur7vueiMIQ</a> &nbsp;Information on how to subscribe, use of proceeds, etc. is sent to both warrant and share holders registered in Sweden and should reach the recipients around March 19. Information is also available on the website&nbsp;<a style="text-decoration:none" href="https://www.dicotpharma.com/en/investor-relations/reports-and-issues/to-6-warrants/">https://www.dicotpharma.com/en/investor-relations/reports-and-issues/to-6-warrants/</a><div></div>